PE20131143A1 - Nuevas aminopirazoloquinazolinas - Google Patents
Nuevas aminopirazoloquinazolinasInfo
- Publication number
- PE20131143A1 PE20131143A1 PE2013000125A PE2013000125A PE20131143A1 PE 20131143 A1 PE20131143 A1 PE 20131143A1 PE 2013000125 A PE2013000125 A PE 2013000125A PE 2013000125 A PE2013000125 A PE 2013000125A PE 20131143 A1 PE20131143 A1 PE 20131143A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- aminopyrazoloquinazolines
- new
- dihydropirazolo
- pyrazole
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 2-DIMETHYLAMINOETHYL Chemical class 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 206010027540 Microcytosis Diseases 0.000 abstract 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A NUEVAS AMINOPIRAZOLOQUINAZOLINAS DE FORMULA (I) DONDE R1 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6 ENTRE OTROS; R2 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, CICLOALQUILO C3-C10, ENTRE OTROS; R3 ES (II) , (III) DONDE A ES UN ARILO C6-C10 Y HETEROARILO C5-C12; B ES UN HETEROARILO NO AROMATICO C5-C7 CON AL MENOS UN HETEROATOMO SELECCIONADO DEL GRUPO N, S Y O, R4 Y R5 ESTAN SELECCIONADOS DEL GRUPO Ra y Rb, Ra ES UN ALQUILO C1-C6, ALQUENILO C2-C6 ENTRE OTROS; Rb ES HALOGENO, -CN, -NO2 ENTRE OTROS; m es 0,1,2,y3; n ES 0 Y 1; X ES -CH2- Y -CH2-CH2- ENTRE OTROS. SON COMPUESTOS PREFERIDOS (5S)-N-[1-(2-METOXIETIL) PIRAZOL-3-IL]-5,8-DIMETIL-9-FENIL-5,6-DIHIDROPIRAZOLO[3,4-H]-QUINAZOLIN-2-AMINA, N-[1-(2-DIMETILAMINOETIL)PIRAZOL-3-IL]-5,8-DIMETIL-9-FENIL-5,6-DIHIDROPIRAZOLO[3,4-H]-QUINAZOLIN-2-AMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA FORMULACION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE CARCINOMAS BRONQUIALES NO MICROCITICOS Y CARCINOMAS HEPATOCITICOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10170683 | 2010-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20131143A1 true PE20131143A1 (es) | 2013-10-23 |
Family
ID=43037625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000125A PE20131143A1 (es) | 2010-07-23 | 2011-07-22 | Nuevas aminopirazoloquinazolinas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8735386B2 (es) |
| EP (1) | EP2595987B1 (es) |
| JP (1) | JP5991974B2 (es) |
| KR (1) | KR20130132394A (es) |
| CN (1) | CN103097388A (es) |
| AP (1) | AP2012006640A0 (es) |
| AR (1) | AR082850A1 (es) |
| AU (1) | AU2011281504A1 (es) |
| BR (1) | BR112013000107A2 (es) |
| CA (1) | CA2803467A1 (es) |
| CL (1) | CL2012003745A1 (es) |
| CO (1) | CO6670575A2 (es) |
| EA (1) | EA201201661A1 (es) |
| EC (1) | ECSP13012448A (es) |
| GE (1) | GEP20156289B (es) |
| MA (1) | MA34389B1 (es) |
| MX (1) | MX2013000821A (es) |
| PE (1) | PE20131143A1 (es) |
| PH (1) | PH12013500152A1 (es) |
| SG (1) | SG187548A1 (es) |
| TW (1) | TW201217380A (es) |
| UY (1) | UY33526A (es) |
| WO (1) | WO2012010704A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2807166B1 (en) | 2012-01-23 | 2016-04-06 | Boehringer Ingelheim International GmbH | 5,8-dihydro-6h-pyrazolo[3,4-h]quinazolines as igf-1r/ir inhibitors |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| EP3546461B1 (en) * | 2013-11-15 | 2021-08-11 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy |
| MX2021001096A (es) | 2015-01-30 | 2023-01-17 | Oncoceutics Inc | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. |
| EP3294742B1 (en) | 2015-05-13 | 2020-01-08 | Boehringer Ingelheim International GmbH | New (5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h)quinazolin-2-yl)-(1h-pyrazol-5-yl)-amines and theri derivatives as igf-1r/1r inhibitors. |
| CN113264935B (zh) * | 2016-11-11 | 2022-09-20 | 上海海雁医药科技有限公司 | 吡啶胺取代的杂三环化合物及其中间体和医药上的用途 |
| US11597725B2 (en) * | 2017-05-26 | 2023-03-07 | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. | URAT1 inhibitor for promoting uric acid excretion |
| CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
| JP2021521282A (ja) * | 2018-04-24 | 2021-08-26 | 上海海雁医薬科技有限公司Ｓｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | Ｃｄｋ４／６阻害剤、その薬学的に許容可能な塩と結晶多形体、及びその応用 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US12311048B2 (en) | 2018-11-02 | 2025-05-27 | Fount Bio, Inc. | Crosslinked materials |
| WO2020160321A1 (en) * | 2019-01-30 | 2020-08-06 | Yale University | Compounds, compositions, and methods for treating fibrosis |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| SG11202108752YA (en) * | 2019-03-07 | 2021-09-29 | BioNTech SE | Process for the preparation of a substituted imidazoquinoline |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| JP7650817B2 (ja) * | 2019-04-19 | 2025-03-25 | ファウント バイオ， インコーポレイテッド | 皮膚内への活性剤の送達および保持 |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| AU2020328025A1 (en) | 2019-08-14 | 2022-03-03 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| CN119930611A (zh) | 2019-10-11 | 2025-05-06 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
| AU2021282596A1 (en) | 2020-06-05 | 2023-01-19 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| CN111960974A (zh) * | 2020-08-28 | 2020-11-20 | 山东潍坊润丰化工股份有限公司 | 一种烯草酮中间体的合成方法 |
| CN116761806B (zh) * | 2021-02-08 | 2025-10-10 | 上海复星医药产业发展有限公司 | 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL123581A (en) * | 1995-10-02 | 2001-09-13 | Hoffmann La Roche | History of pyrimidine as receptor antagonists - 5HT2C, the process for their preparation and drugs containing them |
| BRPI0410563B8 (pt) | 2003-05-22 | 2021-05-25 | Nerviano Medical Sciences Srl | compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas |
| CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
-
2011
- 2011-07-20 US US13/187,100 patent/US8735386B2/en active Active
- 2011-07-21 UY UY0001033526A patent/UY33526A/es not_active Application Discontinuation
- 2011-07-22 KR KR1020137003430A patent/KR20130132394A/ko not_active Withdrawn
- 2011-07-22 PH PH1/2013/500152A patent/PH12013500152A1/en unknown
- 2011-07-22 PE PE2013000125A patent/PE20131143A1/es not_active Application Discontinuation
- 2011-07-22 EA EA201201661A patent/EA201201661A1/ru unknown
- 2011-07-22 AR ARP110102670A patent/AR082850A1/es unknown
- 2011-07-22 JP JP2013520164A patent/JP5991974B2/ja active Active
- 2011-07-22 CN CN201180043930XA patent/CN103097388A/zh active Pending
- 2011-07-22 WO PCT/EP2011/062683 patent/WO2012010704A1/en not_active Ceased
- 2011-07-22 AP AP2012006640A patent/AP2012006640A0/xx unknown
- 2011-07-22 AU AU2011281504A patent/AU2011281504A1/en not_active Abandoned
- 2011-07-22 SG SG2013003645A patent/SG187548A1/en unknown
- 2011-07-22 MX MX2013000821A patent/MX2013000821A/es active IP Right Grant
- 2011-07-22 CA CA2803467A patent/CA2803467A1/en not_active Abandoned
- 2011-07-22 TW TW100126062A patent/TW201217380A/zh unknown
- 2011-07-22 BR BR112013000107A patent/BR112013000107A2/pt not_active IP Right Cessation
- 2011-07-22 EP EP11734158.6A patent/EP2595987B1/en active Active
- 2011-07-22 GE GEAP201113008A patent/GEP20156289B/en unknown
- 2011-07-22 MA MA35577A patent/MA34389B1/fr unknown
-
2012
- 2012-12-28 CL CL2012003745A patent/CL2012003745A1/es unknown
-
2013
- 2013-01-22 CO CO13011464A patent/CO6670575A2/es active IP Right Grant
- 2013-02-19 EC ECSP13012448 patent/ECSP13012448A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2803467A1 (en) | 2012-01-26 |
| MA34389B1 (fr) | 2013-07-03 |
| US8735386B2 (en) | 2014-05-27 |
| US20120238542A1 (en) | 2012-09-20 |
| PH12013500152A1 (en) | 2013-02-18 |
| AU2011281504A1 (en) | 2013-01-10 |
| JP5991974B2 (ja) | 2016-09-14 |
| GEP20156289B (en) | 2015-05-25 |
| SG187548A1 (en) | 2013-03-28 |
| ECSP13012448A (es) | 2013-03-28 |
| AP2012006640A0 (en) | 2012-12-31 |
| MX2013000821A (es) | 2013-05-30 |
| CL2012003745A1 (es) | 2013-05-31 |
| CN103097388A (zh) | 2013-05-08 |
| WO2012010704A1 (en) | 2012-01-26 |
| AR082850A1 (es) | 2013-01-16 |
| KR20130132394A (ko) | 2013-12-04 |
| EA201201661A1 (ru) | 2013-07-30 |
| CO6670575A2 (es) | 2013-05-15 |
| EP2595987B1 (en) | 2018-04-18 |
| EP2595987A1 (en) | 2013-05-29 |
| UY33526A (es) | 2012-02-29 |
| BR112013000107A2 (pt) | 2016-05-17 |
| TW201217380A (en) | 2012-05-01 |
| JP2013532652A (ja) | 2013-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20131143A1 (es) | Nuevas aminopirazoloquinazolinas | |
| EA201992884A2 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| AR090760A1 (es) | Compuestos de benzotiazol y su uso contra el virus de hiv | |
| NZ754039A (en) | Primary carboxamides as btk inhibitors | |
| BR112014006660A2 (pt) | novos derivados de dihidroquinolina-2-ona bicíclicos | |
| EA201592126A1 (ru) | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| PE20181024A1 (es) | Derivados de ciclohexano sustituido con amido | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX2013006847A (es) | Compuesto heterociclico fusionado y su uso para el control de plagas. | |
| EA201792259A1 (ru) | Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения | |
| BR112012013349A2 (pt) | novos compostos tricíclicos | |
| ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| MX387736B (es) | Derivados de fenoximetilo. | |
| EA201501122A8 (ru) | Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4) | |
| ECSP12011684A (es) | Inhibidores de los virus flaviviridae. | |
| ECSP11010830A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| EA201791226A1 (ru) | Композиции, содержащие 2-((1-(2-(4-фторфенил)-2-оксоэтил)пиперидин-4-ил)метил)изоиндолин-1-он для лечения шизофрении | |
| BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
| EA202091400A1 (ru) | Производные пиррола в качестве ингибиторов асс |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |